<SEC-DOCUMENT>0001193125-15-379180.txt : 20151117
<SEC-HEADER>0001193125-15-379180.hdr.sgml : 20151117
<ACCEPTANCE-DATETIME>20151117090505
ACCESSION NUMBER:		0001193125-15-379180
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151110
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151117
DATE AS OF CHANGE:		20151117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NantKwest, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		151237147

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 633-0300

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d20844d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;10, 2015 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>NantKwest,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-37507</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>43-1979754</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3530 John Hopkins Court </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) 633-0300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2015, NantKwest, Inc. (the &#147;Company&#148;) appointed Angela Wilson as the Company&#146;s Chief Financial Officer,
effective as of November&nbsp;13, 2015, replacing Richard Gomberg, who served as the Company&#146;s Chief Financial Officer since January 2010 as an independent contractor pursuant to a services agreement with a financial business management firm.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Wilson (44)&nbsp;joined the Company as Vice President, Finance in October 2015. Ms.&nbsp;Wilson brings over 20 years of
experience providing financial, accounting and tax services to public companies in the life sciences industry. She was with Ernst&nbsp;&amp; Young (EY) for 18 years, last serving as Audit Partner from 2008 through January 2014, where she was
responsible for providing audit and other business services to biotechnology clients such as Abraxis BioScience, Inc. and Peregrine Pharmaceuticals, including public offerings, business combinations, valuations, strategic business planning, systems
conversions, financial reporting, Sarbanes-Oxley compliance and tax compliance and planning. At EY, Ms.&nbsp;Wilson served numerous public clients and was involved in various initial public offerings (IPOs) of biotechnology and health sciences
companies. She has performed Audit Quality Reviews of public biotechnology companies throughout the United States. And Ms.&nbsp;Wilson also served as EY&#146;s West Leader of business resource group to promote women leaders, diversity and
inclusiveness. From October 2014 through April 2015, Ms.&nbsp;Wilson was with Virgin Galactic as Vice President, Finance and Controller, hired to prepare the company for an IPO, and also responsible for financial reporting, budgeting and
forecasting, cash management, overseeing the accounting and finance department and various other areas. Ms.&nbsp;Wilson earned her Bachelor of Science degree in accounting from the University of Tulsa, summa cum laude, and her Masters in Business
Administration from Arizona State University. She is a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and the Southern California Biomedical Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships between Ms.&nbsp;Wilson and any of the directors or executive officers of the Company, and there are no
transactions in which Ms.&nbsp;Wilson has an interest requiring disclosure under Item&nbsp;404(a) of Regulation S-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Wilson
entered into an employment agreement with the Company effective as of October&nbsp;19, 2015 (the &#147;Effective Date&#148;). Ms.&nbsp;Wilson will be paid an annual base salary of $275,000 and she will be eligible to participate in the
Company&#146;s annual bonus program, with a target bonus amount equal to forty-five percent (45%)&nbsp;of her then-current annual base salary. Ms.&nbsp;Wilson is also be eligible to participate in the Company&#146;s employee benefit plans and
programs, including any savings or profit sharing plans, deferred compensation plans, equity incentive plans, and health, disability, insurance and other plans made available generally to the Company&#146;s senior executive officers. Ms.&nbsp;Wilson
was granted 35,000 restricted stock units (RSUs) under the Company&#146;s 2015 Equity Incentive Plan, of which fifty percent (50%)&nbsp;will vest on the second (2nd)&nbsp;anniversary of the vesting commencement date and the remaining fifty percent
(50%)&nbsp;will vest on the fourth (4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> ) anniversary of the vesting commencement date, in each case subject to Ms.&nbsp;Wilson&#146;s continued employment on those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company terminates Ms.&nbsp;Wilson without &#147;cause&#148; (as defined in the Employment Agreement), within
twenty-four (24)&nbsp;months following the Effective Date, the Company will pay Ms.&nbsp;Wilson a single cash payment equal to six (6)&nbsp;months of her then-current salary, less applicable withholding and conditioned upon Ms.&nbsp;Wilson signing a
release of claims in favor of and satisfactory to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Employment Agreement does not purport to be
complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which will be included with the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2015. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Financial Statements and Exhibits</U>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated November 17, 2015</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>NANTKWEST, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: November&nbsp;17, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;/s/ Patrick Soon-Shiong</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick Soon-Shiong</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and
Chairman</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated November 17, 2015</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d20844dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g20844g93r72.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NantKwest Names Angela Wilson Chief Financial Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Culver City, California, November&nbsp;17, 2015 &#151; </B>NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the
power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the appointment of Angela Wilson as chief financial officer (CFO). She succeeds Richard Gomberg, who
served as the company&#146;s CFO since January 2010 as an independent contractor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Angie is an accomplished senior financial executive with
extensive healthcare industry experience,&#148; said Patrick Soon-Shiong, M.D., chairman and chief executive officer of NantKwest. &#147;For more than 20 years, she has provided senior-level financial, accounting and tax services to public
companies. Angie brings a deep understanding of operations and transactions, public offerings, business combinations, Sarbanes-Oxley compliance and strategic business planning. We welcome Angie and look forward to her insights and
contributions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson, a certified public accountant (CPA), first joined NantKwest in October 2015 as vice president, finance. Previously, Wilson
served as vice president, finance and controller for Virgin Galactic, hired to prepare the company for an initial public offering. She began her professional career and served for 18 years with Ernst&nbsp;&amp; Young (EY), a multinational
professional services firm. At E&amp;Y, she rose through the auditing ranks, most recently serving as audit partner, primarily working with biotechnology, pharmaceutical and healthcare companies. Wilson earned a master of business administration
(MBA) degree from Arizona State University and a bachelor in accounting degree, summa cum laude, from the University of Tulsa. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About NantKwest Inc.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune
system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body&#146;s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such
as cancer or virally-infected cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NantKwest&#146;s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer
therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1)&nbsp;Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell
contact, (2)&nbsp;Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3)&nbsp;Targeted
activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk
of serious &#147;cytokine storms&#148; reported after T cell therapy. As an &#147;off-the-shelf&#148; therapy, NantKwest&#146;s NK cells do not rely on a patient&#146;s own often compromised immune system. In Phase 1 clinical trials in patients with
late stage cancer, NantKwest&#146;s NK cells have been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage,
immuno-oncology programs that include a Phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy
company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">#
# # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NantKwest </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jen Hodson, 562-397-3639 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jhodson@nantworks.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g20844g93r72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20844g93r72.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !? 2L# 2(  A$! Q$!_\0
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M=7SO\&O@UX@^/?Q L_#?AJR:\U&[.6)XBM8QC=+(W\*#U[\ 9)Q7Z??LN_\
M!.+P)^SYIUM=WUG;^*O%  :74;Z$/'$_<0Q'*H!V/+>_:NFI&C25FKLYJ<JU
M5W3LCC_V6O\ @H'\0?C+=V\>L_"#7I+"=@O]KZ/&PMXP?XBL^T$?[KGZ&OK5
M3D#Z4*H5< 8 X ':EKSYM-Z*QZ$(M*S=PHHHJ2@HHHH **** "BBB@ HHHH
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M++Q+X<O))(8KRV# >8AVNC*P#*P/4, >GK7:5^?7_!M*,?\ !.&7_L;=1_\
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MJT?;?S^[Z?US'S<+?VT_9_RZ_P!?<=?_ ,'#/_*+KQ?_ -A+2_\ TLCKP/\
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M\5^"1_8T>IP1Z0XDMIUO(8I3NC?'S*< /P<9!%>9_P#!SV ?V$/#7MXPMO\
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M^6WXF=^TA\9?$'CWXHP?#'P3,UI=S$)J-ZC%63*[F0,.555Y8CDYP/>[H_\
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M -?ES_Z,-9PQ=98&Z>SM\K&U3 8>69<KCHXWZ[WW/90.:6BBO%/HSQ?]OO\
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MQ_S_ *T/0RS+%A8N4WS3ENSXC_X.&?\ E%WXP_["6E_^ED=7/^#?XX_X)<>
M_>YU''_@9+7U?\5OA-X<^./@'4O"WB[1K#Q!X=UB+R;W3[V+S(;A00PR/4$
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46"-410J* JJHP% Z "G5P'J'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
